• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Target ALS

A New York based ALS research organization that's leading the fight for a cure.

  • DONATE
  • About Us
    • Our Mission
    • Our Model
    • Our Impact
    • Our Founder
    • Our Team
    • Our Partners
  • For Scientists
    • Research Cores
      • Target ALS Data Engine
      • Longitudinal Biofluids Core
      • Human Postmortem Tissue Core
      • Stem Cell Core
      • Reagents Core
      • Animal Models Core
    • Funding Opportunities
    • Funded Projects
    • Annual Meeting
    • Science on Target Blog
  • Understanding ALS
    • About ALS
    • Understanding the Science
      • Glossary
      • FAQ
      • ALS 101
    • Voices of ALS
    • Video Library
  • Take Action
    • ALS Awareness Month:
      Behind the Breakthrough
    • Support Geoff Greulich
    • The ALS Global Research Initiative (AGRI)
      • Global Natural History Study
      • Community Based Pop-Up Clinics
    • Ways to Give
    • Email Sign Up
    • Contact Us
    • Donate Now
  • News
    • Announcements
    • In the News
    • Newsletters & Reports

Our Team

Target ALS Team

We have built a team that brings together a unique mix of clinical, scientific, business, and philanthropic expertise.

Jessica Chapman, MBA, CAP
Chief Development Officer
Connect on LinkedIn
Courtney Christa
Accounts Payable Specialist
Connect on LinkedIn
Kenneth
Kenneth Devaney
Chief Operations Officer
Connect on LinkedIn
Laura Dugom
Laura Dugom
Clinical Research Scientist
Connect on LinkedIn
Amy Easton
Amy Easton, Ph.D.
Senior Director of Scientific Programs
Connect on LinkedIn
Aiden Hipwell, MBA
Marketing Coordinator
Connect on LinkedIn
Ruby Hoglund
Administrative Assistant
Connect on LinkedIn
Stephanie Ishoo
Stephanie Ishoo
Manager, Research Communications and Marketing
Connect on LinkedIn
Ariella Leicht
Development Operations Manager
Connect on LinkedIn
Christine Aranyos Prouty
Director of Philanthropy
Connect on LinkedIn
Manish Raisinghani
Manish Raisinghani, M.B.B.S., Ph.D.
Chief Executive Officer
Connect on LinkedIn
Clint Ramnarine
Clint Ramnarine
Grants & Database Manager
Connect on LinkedIn
Yuliya Rzad
Yuliya Rzad
Chief Grants Officer
Connect on LinkedIn
ALS researcher
Burhan Siddiqui
Accounting & Financial Systems Manager
Connect on LinkedIn
Tammy Sutherns
Manager of Mission Communications
Connect on LinkedIn
Daniel Weatherill, Ph.D.
Data Scientist
Connect on LinkedIn

Foundation Advisors

Our Foundation Advisors guide the Target ALS administration in ensuring that we are following best-in-class scientific approaches in our work, and they keep us closely connected to the latest developments in the field.

Leonard Petrucelli, Ph.D.
Leonard Petrucelli, Ph.D.
Chief Scientific Advisor, Target ALS
Professor of Neuroscience, Mayo Clinic

Board Members

The Target ALS Board of Directors sets overall policy and provides guidance to the Foundation’s executive leadership team. To ensure we craft truly groundbreaking strategies to foster collaboration and accelerate drug discovery and development, we have recruited a renowned, passionate group of pioneering academic leaders, pharmaceutical and biotech executives, patients and their family members, and visionary philanthropists.

Dan Doctoroff
Daniel L. Doctoroff
Founder & Board Chair, Target ALS
Founder & Former CEO, Sidewalk Labs Former CEO, Bloomberg LP Former Deputy Mayor of Economic Development and Rebuilding for the City of New York
Andy Berndt
Andy Berndt
Vice President and Co-Founder,
Google Creative Lab
Alisa Doctoroff
Alisa Doctoroff
Philanthropist
John
John Dunlop, Ph.D.
Former Chief Scientific Officer,
Aliada Therapeutics
Steven Gruber
Investor
Zach Hall, PhD
Zach Hall, Ph.D.
Former Director,
NIH NINDS
Richard Hargreaves
Richard Hargreaves, Ph.D.
Corporate Vice President,
Bristol-Myers Squibb
Henderson
Chris Henderson, Ph.D.
Former Chief Scientific Officer,
Alltrna
female scientist
Carole Ho, M.D.
Chief Medical Officer & Head of Development,
Denali Therapeutics
Allison Jaffin
Chief Operating Officer,
Bloomberg Philanthropies
Brad S Karp
Brad S. Karp
Chairman,
Paul, Weiss, Rifkind, Wharton & Garrison LLP
Landis
Story Landis, Ph.D.
Former Director, NIH NINDS, Board Liaison, Independent Review Committee
Sarah Sheikh
Sarah I. Sheikh, BM BCh, MSc, MRCP
Senior Vice President, Neuroscience
Takeda
Stacie Weninger, Ph.D.
President and Venture Partner,
F-Prime Biomedical Research Initiative

Independent Review Committee

The Target ALS Independent Review Committee (IRC) evaluates and makes all research funding decisions. The IRC is comprised of experts across scientific disciplines from both industry and academia, reflecting the evolving nature of ALS research. To avoid any possible conflicts of interest, no member of the IRC can apply for or receive Target ALS funding for their own research. The committee is chaired by Robert Miller, Ph.D., George Washington University.

Michaek Ahlijanian
Michael Ahlijanian, Ph.D
Chief Scientific Officer,
Pinteon Therapeutics
Eva Maria Albers
Eva-maria Albers, Ph.D.
Professor and Group Leader, Institute for Developmental Biology and Neurobiology (IDN)
Johannes Gutenberg Universität Mainz
Sophia Bardehle
Sophia Bardehle, Ph.D.
Senior Principal Scientist, In Vivo Pharmacology,
Abbvie
Manzoor
Manzoor Bhat, Ph.D., M.S.
Vice Dean for Research (Interim), Professor and Chair,
UT Health Science Center, San Antonio
Dean Brown, Ph.D.
SVP and Head of Discovery Sciences,
Jnana Therapeutics
Elizabeth D. Buttermore, PhD
Elizabeth D. Buttermore, Ph.D.
Director of Translational In Vitro Models,
Rosamund Stone Zander Translational Neuroscience Center, Boston Children’s Hospital
Moses Chao
Moses Chao, Ph.D.
Professor, Department of Neuroscience
and Physiology,
New York University
Merit E Cudkowicz
Merit Cudkowicz, M.D.
Chief, Neurology Department; Director, Sean M. Healey & AMG Center for ALS; Julieanne Dorn Professor of Neurology,
Harvard Medical School
Vardhan Dani, Ph.D.
Michela Deleidi, M.D., Ph.D.
Helmholtz Group Leader, DZNE German Center for Neurodegenerative Diseases,
University of Tübingen
Nino Devidze, Ph.D.
VP, Medical,
SSI Strategy
Biljana Djukic, Ph.D.
Translational Medicine and Early Development Lead, Neurology and Rare Diseases,
Sanofi
Fanny Elahi, M.D., Ph.D.
Associate Professor
Icahn School of Medicine at Mount Sinai
Lisa Ellerby
Lisa Ellerby, Ph.D.
Professor,
Buck Institute
Kurt
Kenneth Fischbeck, M.D.
NIH Distinguished Investigator,
NIH NINDS
Ana Fiszbein, Ph.D.
Assistant Professor of Biology,
Boston University
Brad Friedman
Brad Friedman, Ph.D.
Senior Principal Scientist, Department of OMNI Bioinformatics,
Genentech, Inc.
Judith Frydman
Judith Frydman, Ph.D.
Donald Kennedy Chair, School of Humanities and Sciences and Professor of Genetics,
Frydman Lab, Stanford University
Sonia Gandhi, M.D., Ph.D.
Professor of Neurology,
UCL and The Francis Crick Institute
Volkan Granit
Volkan Granit, MD, MSc
Medical Director, Clinical Development,
Biohaven Pharmaceuticals
Professor Orla hardiman
Orla Hardiman, M.D., FRCPI
Professor of Neurology/Head of Academic, Clinical Medicine,
Trinity College of Dublin
Erika Holzbaur
Erika Holzbaur, Ph.D.
Professor of Physiology,
University of Pennsylvania, Perelman School of Medicine
Eric Huang, M.D., Ph.D.
Edward Mallinckrodt Professor & Chair,
Department of Pathology and Immunology, Washington University School of Medicine
Aimee Kao
Aimee Kao, M.D., Ph.D.
John Douglas French Foundation Endowed Professor; Director, Medical Scientist Training Program,
Memory and Aging Center, University of California, San Francisco
Zaven
Zaven Kaprielian, Ph.D.
Chief Scientific Officer,
Remix Therapeutics
Ionis Holly Kordasiewicz
Holly Kordasiewicz, Ph.D.
Vice President, Neurology Research,
Ionis Pharmaceuticals
Sarah Kucenas
Sarah Kucenas, Ph.D
Professor of Biology, Cell Biology, and Neuroscience,
University of Virginia
Jim Kupiec, M.D.
Chief Clinical Development Officer,
Cassava Sciences
Claire Le Pichon, Ph.D.
Principal Investigator,
NIH Unit on the Development of Neurodegeneration
Pam Maher
Pamela Maher, Ph.D.
Research Professor, Cellular Neurobiology Laboratory,
Salk Institute
Robert
Robert Mays, Ph.D.
Roche Alexander McCampbell
Alexander McCampbell, Ph.D.
Global Head of Neuroscience & Rare Diseases Research,
Roche
Gere Meredith
Jere Meredith, Jr., Ph.D.
Senior Director, Head of Neurology Discovery,
Eisai Co, Ltd
Axel Methner, M.D.
Professor of Neurology,
University Medical Center Mainz
Dr. Robert Miller
Robert Miller, Ph.D.
Chair, Target ALS IRC
Vice Dean for Research & Academic Affairs, George Washington University
Kelly Monk
Kelly Monk, Ph.D
Co-Director,
Vollum Institute
Ralda Nehme, Ph.D.
Principal Investigator & Director of Stem Cell Program,
Stanley Center for Psychiatric Research, Broad Institute of MIT & Harvard
Richard Hargreaves
Richard Olson, Ph.D.
Director, Small Molecule Drug Discovery,
Bristol Myers Squibb
Manuela Polydoro, Ph.D.
VP, Head of Translational Medicine,
Muna Therapeutics
MRao
Mahendra Rao, M.D., Ph.D.
Chief Executive Officer,
Implant Therapeutics
Ian
Ian Reynolds, Ph.D.
President,
YaghPenn Consulting
Tracy Saxton
Tracy Saxton, Ph.D.
Managing Director,
Saxton Biopharma Consulting, LLC
Rob Scannevin, PhD
Rob Scannevin, Ph.D.
Chief Scientific Officer,
Verge Genomics
Eric
Eric Schaeffer, Ph.D.
President,
Schaeffer Biopharma Consulting
Kimberly Scearce-Levie
Kimberly Scearce-Levie, Ph.D.
Chief Development Officer,
Cajal Neuroscience
Abdoulaye Sene, Ph.D.
VP, Translational Science, Ophthalmology,
Kartos Therapeutics
Holly Soares
Holly Soares, Ph.D.
Global Head Neuroscience and Rare Disease Biomarkers, VP
Roche
Ajay
Ajay Verma, M.D., Ph.D.
Ottavio Vitolo, M.D.
Lecturer on Psychology, Harvard University, Co-Founder, President and CEO, Vitam Therapeutics, Inc.,
Neuropsychiatrist, Massachusetts General Hospital
Frank
Frank Walsh, Ph.D.
Founder and Chief Executive Officer,
Ossianix
Andrew
Andrew Wood, Ph.D.
VP, Clinical Neuroimaging Research,
CHDI
Nicholas Wood, Ph.Dd, FRCP, FMedSci
UCL Professor of Genetics and Neurology,
University College London, Institute of Neurology
Choya Yoon
Choya Yoon, Ph.D.
Associate Principal Scientist,
Merck
Stephen Zicha, Ph.D.
Neuroscience Search & Evaluation,
Eli Lilly & Co.

Conflict of Interest Committee

To avoid Conflicts of Interest (COI), all board and committee members, as well as staff, abide by a comprehensive COI policy and are neither allowed to apply for, nor receive funding from, Target ALS.

Henderson
Chris Henderson, Ph.D.
Former Chief Scientific Officer,
Alltrna
Brad S Karp
Brad S. Karp
Chairman,
Paul, Weiss, Rifkind, Wharton & Garrison LLP
Dr. Robert Miller
Robert Miller, Ph.D.
Chair, Target ALS IRC
Vice Dean for Research & Academic Affairs, George Washington University

Footer

Target ALS
  • Donate
  • Contact
  • Financial Reports
  • Call For Proposals
  • Annual Meeting
  • Privacy Policy
  • Credits

Follow Us

guidestar

We are a 501(c)(3) public charity (EIN: 81-0756743), eligible to receive tax-deductible contributions that directly support our mission to break down barriers to ALS research to find effective treatments.

The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, click here.

© 2023 Target ALS Foundation, Inc.
Target ALS Foundation
244 Madison Avenue #1025
New York, NY 10016
(332) 333-4140
Steck Insights WordPress Consulting

Join us this ALS Awareness Month to discover the people, stories, and science accelerating progress in ALS research.

Name(Required)
Interests(Required)
Mark the options that best describe your interest in ALS